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Abstract: Vitamin D has many effects on cells in the immune system. Many studies have linked low
vitamin D status with severity of COVID-19. Genetic variants involved in vitamin D metabolism have
been implicated as potential risk factors for severe COVID-19 outcomes. This study investigated how
genetic variations in humans affected the clinical presentation of COVID-19. In total, 646 patients
with SARS-CoV-2 infection were divided into two groups: noncritical COVID-19 (n = 453; 70.12%)
and a critical group (n = 193; 29.87%). Genotype data on the GC, NADSYN1, VDR, and CYP2R1
genes along with data on serum 25-hydroxyvitamin D levels were compiled in patients admitted to
a major hospital in the United Arab Emirates between April 2020 and January 2021. We identified
12 single-nucleotide polymorphisms associated with the critical COVID-19 condition: rs59241277,
rs113574864, rs182901986, rs60349934, and rs113876500; rs4944076, rs4944997, rs4944998, rs4944979,
and rs10898210; and rs11574018 and rs11574024. We report significant associations between genetic
determinants of vitamin D metabolism and COVID-19 severity in the UAE population. Further
research needed to clarify the mechanism of action against viral infection in vitamin D deficiency.
These variants could be used with vaccination to manage the spread of SARS-CoV-2 and could be
particularly valuable in populations in which vitamin D deficiency is common.
Keywords: vitamin D; metabolism; polymorphism; COVID-19; UAE; genotypes
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1. Introduction
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In late 2019, the first cases of COVID-19, caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), were reported in Wuhan, China [1]. Phenotypic
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heterogeneity has been observed in COVID-19 cases, with symptoms characterized as
asymptomatic, mild, moderate, and severe, with evidence that the hyperinflammatory
responses induced by SARS-CoV-2 are the major causes of disease severity and death [2].
In addition, several studies have shown that individuals with comorbidities, such as
obesity, hypertension, type 2 diabetes, and cardiovascular diseases, are more susceptible to
developing severe COVID-19 symptoms owing to an imbalance in the immune response
and uncontrolled release of proinflammatory cytokines [3]. While worldwide vaccination
efforts are still underway with unequal and mismatched rates among countries, efforts
continue to be directed toward treatments, which aim to reduce the number of severe cases
and deaths.
One strategy to reduce severe COVID-19 symptoms relies on high-dose biological
factors, vitamins, and trace elements, such as vitamin D, zinc, and selenium [4]. Vitamin D
has been identified as an important molecule in attenuating the SARS-CoV-2 viral infection
through binding to the vitamin D receptor (VDR) to control the immune response [5,6].
Moreover, vitamin D had been identified by novel genomics-guided tracing research as
a promising candidate molecule through orchestrating the expression of immune-related
genes with potential to reduce SARS-CoV-2 viral infection through binding to the VDR [7].
Specific variants in genes involved in vitamin D metabolism have been identified as potential risk factors for severe COVID-19 outcomes [8], but research in this area remains limited.
We recently showed that severe vitamin D deficiency strongly correlated with COVID19 severity and death among patients in the UAE [9]. Furthermore, genetic polymorphisms
in the VDR gene affect the susceptibility to certain chronic diseases, such as diabetes and
obesity [10]. Therefore, genetic variants in vitamin D metabolism and VDR genes could be
important factors in determining COVID-19 disease severity and progression. This study
aimed to examine the association of polymorphisms in VDR and other genes involved in
vitamin D metabolism with COVID-19 disease outcome among the UAE population.
2. Materials and Methods
2.1. Participants and Collecting Samples
A total of 646 participants who tested positive for SARS-CoV-2 by real-time PCR via
nasopharyngeal swabs were recruited from the Sheikh Khalifa Medical City, quarantine
area in Abu Dhabi, and Rashid Hospital, in Dubai, between April 2020 and January 2021.
This study was approved by the Abu Dhabi Health COVID-19 Research Ethics Committee (DOH/DQD/2020/538), the Dubai Scientific Research Ethics Committee (DSREC04/2020_09), and the SEHA Research Ethics Committee (SEHA-IRB-005). Details about
participant recruitment and data collection were outlined previously [9].
2.2. Collecting Demographic Data
Clinical and demographic data were collected from participants and medical staff at
the hospital and quarantine area. Participants were divided into two groups: noncritical
patients (n = 453) and critical patients (n = 193). Noncritical illness was defined as nonhospitalized patients with asymptomatic to mild symptoms. Critical illness was defined as
patients who have SpO2 <94% in room air at sea level, a ratio of arterial partial pressure
of oxygen to fraction of inspired oxygen (PaO2 /FiO2 ) <300 mmHg, respiratory frequency
>30 breaths/min, or lung infiltrates >50% that require hospital admission because of use of
mechanical ventilation, supplemental oxygen therapy, progression to respiratory failure,
and severe complications, such as septic shock or multiorgan failure. Among participants
who reported a comorbidity, critical COVID-19 patients were more likely to have had a previous diagnosis of cardiovascular disease (arrhythmias, congenital heart disease, coronary
artery disease, deep vein thrombosis, myocardial infarction, cardiomyopathy; p < 0.001) or
chronic lung disease (asthma, pneumonia, bronchitis, pneumothorax).
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2.3. DNA Extracting and Genotyping
A total of 2 mL of blood was collected by a qualified nurse in an EDTA tube. Samples
were transferred to the Khalifa University Center for Biotechnology’s laboratory for DNA
extraction and genotyping. DNA was extracted according to the manufacturer’s instructions. DNA was quantified using a DS-11 Series spectrophotometer/fluorometer (DeNovix,
Wilmington, Delaware, USA). Genotyping was performed using the Infinium Global Screening Array (Illumina, San Diego, CA, USA) according to the manufacturer’s protocol. The
Infinium array contained 654,027 genetic markers. Genotypes were prephased and imputed
using the Phase 3 1000 Genomes Projects panel, carried out with BEAGLE, using standard
protocols and recommended settings. Post-imputation quality controls were conducted,
and 9,175,654 variants passed filters. The locations of the following single-nucleotide
polymorphisms (SNPs) were extracted: GC in chromosome 4, DHCR7/NADSYN1 in chromosome 11, VDR in chromosome 12, and CYP2R1 in chromosome 11.
2.4. Measuring Serum 25(OH)D Levels
A total of 2 mL of blood was collected by a qualified nurse in a gel tube to measure
levels of total 25-hydroxyvitamin D [25(OH)D] with automated electrochemiluminescence
(Elecsys 2010; Roche Diagnostics, GmbH, Mannheim, Germany). The detection limit of
serum 25(OH)D was 4 ng/mL. The intra-assay coefficient of variation was 5%, and the
interassay coefficient was 7.5%.
2.5. Statistical Analysis
Statistical analysis was conducted as a case–control panel, with controls characterized as noncritical symptoms and cases characterized as critical symptoms, using PLINK
(version 1.9) and SPSS (version 16.0; SPSS, Chicago, IL, USA). Cross-tabulation and chisquare test were used to evaluate the association between clinical severity of disease with
symptomatology and risk factors. Genomewide association study (GWAS) screening was
performed with the χ2 statistic. To control for population stratification, the first 10 eigenvectors were used in later adjustment analyses. The adjusted analysis corrected for age,
sex, and population stratification. To assess the association of a given SNP with COVID-19
severity, the allelic frequencies were compared by means of a χ2 statistic, which yielded
an individual p-value for each combination of SNP and genetic model. The p-values were
not adjusted for multiple testing because of the explorative nature of the original GWAS.
Haplotype analysis was performed to estimate the genetic contribution of haplotypes to
COVID-19 severity, which can be more informative and powerful than the association of
individual variants.
3. Results
Table 1 summarizes demographic data of the 646 participants, divided as described
above. Critical COVID-19 patients were older (p < 0.001), with higher body mass index
(BMI; kilograms per square meter of body surface area; p = 0.001), of Middle Eastern or
Asian ethnicities (p = 0.004), and suffering from one or more comorbidities (p < 0.001).
Male patients were not at higher risk of developing severe/critical disease than female
patients (p = 0.22). Among participants who reported a comorbidity, critical COVID-19
patients were more likely to have had a previous diagnosis of cardiovascular disease
(arrhythmias, congenital heart disease, coronary artery disease, deep vein thrombosis, myocardial infarction, cardiomyopathy; p < 0.001) or chronic lung disease (asthma, pneumonia,
bronchitis, pneumothorax).
To investigate the association of 25(OH)D with risk of critical COVID-19 disease,
serum 25(OH)D levels were measured in some participants (Table 2). After adjustment for
age, sex, nationality, and BMI, critical COVID-19 patients were more likely to be severely
vitamin D deficient (OR = 4.37 [95% CI, 2.06–9.29]; p < 0.001) than noncritical COVID-19
patients.
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Table 1. Demographics of study participants.
Noncritical, n = 453 (%)

Critical, n = 193 (%)

<33

155 (34.2)

12 (6.2)

34–43

138 (30.5)

31 (16.1)

44–55

92 (20.3)

60 (31.1)

>56

68 (15.0)

90 (46.6)

Male

305 (77.2)

70 (83.3)

Female

90 (22.8)

14 (16.7)

<18.50

9 (2.3)

1 (0.5)

18.51–24.90

115 (29.4)

38 (19.7)

24.91–29.99

168 (43.0)

77 (39.9)

>30.00

99 (25.3)

77 (39.9)

Middle Eastern

40 (30.9)

80 (41.5)

Asian

290 (64.0)

103 (53.4)

African

18 (4.0)

3 (1.6)

European

2 (0.4)

5 (2.6)

American

3 (0.7)

2 (1.0)

No

263 (65.1)

75 (40.3)

Yes

141 (34.9)

111 (59.7)

No

279 (75.4)

78 (47.3)

Yes

91 (24.6)

87 (52.7)

No

250 (93.6)

117 (90.0)

Yes

17 (6.4)

13 (10.0)

No

323 (99.4)

128 (96.2)

Yes

2 (0.6)

5 (3.8)

No

318 (95.8)

112 (83.0)

Yes

14 (4.2)

23 (17.0)

No

320 (98.8)

126 (95.5)

Yes

4 (1.2)

6 (4.5)

No

312 (94.8)

111 (78.7)

Yes

17 (5.2)

30 (21.3)

Variable

p

Age
<0.001

Sex
0.217

Body mass index (kg/m2 of
body surface area)
0.001

Country of origin
0.004

History of comorbid condition
<0.001

Diabetes
<0.001

Immunosuppressive condition
0.20

Liver disease
0.01

Metabolic disease
<0.001

Neurological disorder
0.03

Renal disease
<0.001
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Table 1. Cont.
Noncritical, n = 453 (%)

Critical, n = 193 (%)

p

No

312 (91.5)

111 (76.0)

<0.001

Yes

29 (8.5)

35 (24.0)

No

318 (97.2)

113 (86.3)

Yes

9 (2.8)

18 (13.7)

Variable
Cardiac condition

Chronic lung condition
<0.001

Table 2. Association of 25(OH)D status with risk of critical COVID-19 disease.
25(OH)D Status
(ng/mL)

Noncritical,
n = 322 (%)

Critical,
n = 155 (%)

Normal (>20)

90 (28.0)

56 (36.1)

Deficient (<20)

142 (44.1)

47 (30.3)

Severely deficient (<12)

90 (28.0)

52 (33.5)

Unadjusted
OR (95% CI)

p

p

Adjusted
OR (95% CI)

1.00
0.02

p

1.00

0.54
(0.35–0.89)

0.008

1.28
(0.62–2.65)

0.49

0.95
(0.59–1.51)

0.93

4.37
(2.06–9.29)

<0.001

To further investigate genetic effects between COVID-19 phenotype and vitamin D, all
SNPs (total of 578) located in the GC gene (chromosome 4, 72607410–72671237; 168 SNPs),
DHCR7/NADSYN1 (chromosome 11, 71164249–71212862; 230 SNPs), VDR (chromosome
12, 48235320–48298777; 154 SNPs), and CYP2R1 (chromosome 11, 14898986–14913777;
9 SNPs) were extracted. Those SNPs are involved in synthesis, transport, and metabolism
of vitamin D and the VDR. The COVID-19 phenotype was dichotomously classified into the
critical group (n = 453) and the noncritical group (n = 193). Imputation in this multiancestry
cohort was performed to increase power. Thus, SNPs included in the dataset were imputed
SNPs and tag SNPs. Table 3 shows the top five SNPs significant for each gene, and the
remaining SNPs are listed in Supplementary Table S1. Supplementary Table S2 includes the
genotype data and genetic model, whereas Supplementary Table S3 includes the haplotype
association model.
Table 3. Association of analyzed genotypes with risk of critical COVID-19 disease.
Gene

GC

SNP

Genotype

Noncritical,
n = 453 (%)

Critical,
n = 193 (%)

Genetic Model

Unadjusted OR
(95% CI)

p

Adjusted OR
(95% CI)

p

rs59241277

AA
AG
GG

363 (80.1)
86 (19.0)
4 (0.9)

174 (90.2)
18 (9.3)
1 (0.5)

AA vs. AG + GG

0.47
(0.28–0.77)

0.003

0.43
(0.24–0.77)

0.005

rs113574864

CC
CT
TT

350 (77.3)
96 (21.2)
7 (1.5)

168 (87.0)
23 (11.9)
2 (1.1)

CC vs. CT + TT

0.47
(0.29–078)

0.003

0.43
(0.24–0.78)

0.005

rs182901986

GG
GA
AA

354 (78.1)
93 (20.5)
6 (1.3)

171 (88.6)
20 (10.4)
2 (1.0)

GG vs. GA + AA

0.50
(0.31–0.80)

0.003

0.49
(0.29–0.84)

0.01

rs60349934

TT
TC
CC

359 (79.2)
91 (20.1)
3 (0.7)

170 (88.1)
22 (11.4)
1 (0.5)

TT vs. TC + CC

0.55
(0.34–0.87)

0.011

0.50
(0.28–0.86)

0.01

rs113876500

GG
GT
TT

350 (77.3)
96 (21.2)
7 (1.5)

168 (87.1)
23 (11.9)
2 (1.0)

GG vs. GT + TT

0.54
(0.35–0.84)

0.006

0.53
(0.31–0.88)

0.02
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Table 3. Cont.
Gene

NADSYN1

VDR

CYP2R1

SNP

Genotype

Noncritical,
n = 453 (%)

Critical,
n = 193 (%)

Genetic Model

Unadjusted OR
(95% CI)

p

Adjusted OR
(95% CI)

p

rs4944076

AA
AG
GG

148 (32.7)
198 (43.7)
107 (23.6)

78 (40.4)
93 (48.2)
22 (11.4)

AA vs. AG + GG

0.66
(0.51–0.84)

0.001

0.66
(0.49–0.90)

0.008

rs4944997

GG
GA
AA

144 (31.8)
199 (43.9)
110 (24.3)

73 (37.8)
95 (49.2)
25 (13.0)

GG vs. GA + AA

0.69
(0.54–0.89)

0.004

0.69
(0.51–0.93)

0.02

rs4944998

GG
GC
CC

144 (31.8)
200 (44.2)
109 (24.1)

73 (37.8)
95 (49.2)
25 (13.0)

GG vs. GC + CC

0.70
(0.55–0.89)

0.004

0.70
(0.51–0.94)

0.02

rs4944979

GG
GT
TT

146 (32.2)
197 (43.5)
110 (24.3)

74 (38.3)
94 (48.7)
25 (13.0)

GG vs. GT + TT

0.69
(0.54–0.89)

0.004

0.70
(0.52–0.94)

0.02

rs10898210

AA
AG
GG

157 (34.7)
196 (45.2)
100 (22.1)

85 (44.0)
87 (45.1)
21 (10.9)

AA vs. AG + GG

0.64
(0.50–0.82)

0.0005

0.67
(0.50–0.90)

0.009

rs11574018

TT
TC
CC

438 (96.7)
15 (3.3)
0 (0.0)

192 (99.5)
1 (0.5)
0 (0.0)

TT vs. TC + CC

0.15
(0.02–1.17)

0.051

0.10
(0.01–0.86)

0.04

rs11574024

GG
GT
TT

440 (97.1)
13 (2.9)
0 (0.0)

190 (98.4)
3 (1.6)
0 (0.0)

GG vs. GT + TT

0.53
(0.15–1.89)

0.328

0.20
(0.04–0.91)

0.04

rs116886958

CC
CA
AA

428 (94.5)
25 (5.5)
0 (0.0)

187 (96.9)
6 (3.1)
0 (0.0)

CC vs. CA + AA

0.55
(0.22–1.36)

0.195

0.37
(0.13–1.04)

0.06

rs10875694

TT
TA
AA

359 (79.2)
90 (19.9)
4 (0.9)

158 (81.9)
32 (16.6)
3 (1.6)

TT vs. TA + AA

0.90
(0.60–1.33)

0.602

0.63
(0.13–1.02)

0.06

rs2239181

AA
AC
CC

429 (94.7)
24 (5.3)
0 (0.0)

176 (91.2)
15 (7.8)
2 (1.0)

AA + AC vs. CC

1.00
(0.71–1.41)

0.996

1.44
(0.95–2.18)

0.08

rs11023373

GG
GC
CC

426 (94.0)
23 (5.1)
4 (0.9)

188 (97.4)
5 (2.6)
0 (0.0)

GG vs. GC + CC

0.37
(0.14–0.95)

0.034

0.39
(0.13–1.15)

0.09

rs11023374

TT
TC
CC

284 (62.7)
147 (32.5)
22 (4.9)

130 (67.4)
55 (28.5)
8 (4.1)

TT vs. TC + CC

0.84
(0.62–1.14)

0.271

0.73
(0.51–1.05)

0.09

rs10500804

TT
TG
GG

165 (36.4)
209 (46.1)
79 (17.4)

78 (40.4)
83 (43.0)
32 (16.6)

TT vs. TG + GG

0.90
(0.70–1.15)

0.415

0.83
(0.61–1.11)

0.22

rs1993116

GG
GA
AA

192 (42.4)
205 (45.3)
56 (12.4)

75 (38.9)
91 (47.2)
27 (14.0)

GG + GA vs. AA

1.11
(0.87–1.43)

0.377

1.24
(0.92–1.69)

0.15

rs7935792

AA
AC
CC

362 (79.9)
84 (18.5)
7 (1.5)

157 (81.3)
33 (17.1)
3 (1.6)

AA vs. AC + CC

0.92
(0.62–1.37)

0.703

1.00
(0.61–1.65)

0.99

An additive (dominant) genetic model was applied for the genetic model where the homozygous genotype of the more frequent allele
was compared with the heterozygous genotype and homozygous genotype of the less frequent allele. Adjusted for age, sex, population
stratification; OR = odds ratio; SNP = single-nucleotide polymorphism. Data are presented as frequencies (%) and OR (95% CI); p < 0.05
considered significant (shown in boldface).

Specific SNPs located in the genes GC, DHCR7/NADSYN1, and VDR were associated
with the critical COVID-19 condition among patients. However, no SNPs examined in
gene CYP2R1 were associated with risk of critical COVID-19 condition. For gene GC, the
AA genotype in SNP rs59241277 (p = 0.005), CC genotype in SNP rs113574864 (p = 0.005),
GG genotype in SNP rs182901986 (p = 0.01), TT genotype in SNP rs60349934 (p = 0.01),
and GG genotype in SNP rs113876500 (p = 0.02) were associated with the critical COVID19 condition. For gene DHCR7/NADSYN1, AA genotype in SNP rs4944076 (p = 0.008),
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GG genotype in SNP rs4944997 (p = 0.02), GG genotype in SNP rs4944998 (p = 0.02), GG
genotype in SNP rs4944979 (p = 0.02), and AA genotype in SNP rs10898210 (p = 0.009) were
similarly associated with severity, whereas for gene VDR, TT genotype in SNP rs11574018
(p = 0.04) and GG genotype in SNP rs11574024 (p = 0.04) were significant.
As shown in Supplementary Table S1, 20 blocks are incorporated within the four
genomic regions: GC, DHCR7/NADSYN1, CYP2R1, and VDR. The following haplotype
windows (Supplementary Table S3) were associated with the critical COVID-19 condition
among patients: VDR gene (block 7 [p = 0.01], block 10 [p = 0.04]), DHCR7/NADSYN1 gene
(block 11 [p = 0.03]), and GC gene (block 15 [p = 0.003; p = 0.0004], block 16 [p = 0.003;
p = 0.003], block 17 [p = 0.003], block 18 [p = 0.003; p = 0.03], block 19 [p = 0.02], block 20
[p = 0.004; p = 0.002]).
4. Discussion
To the best of our knowledge, this study is the first to examine the contribution of genetic variants of vitamin D metabolism to COVID-19 disease severity. Specifically, 25(OH)D
levels, which reflect vitamin D status in the body, were measured in a cohort of patients
who tested positive for SARS-CoV-2 in the UAE. With 63% of critical patients having
deficient or severely deficient vitamin D levels, the plausible association with severity of
viral infections was examined. These findings also accord with findings associating lower
vitamin D levels (<12 ng/mL) with increased risk of critical COVID-19 condition [9]. Specific variants in genes involved in vitamin D metabolism have been proposed as potential
risk factors for severe COVID-19 outcomes [11], but specific research in this context remain
limited. In this study, we analyzed several variants in the loci near protein-coding genes
involved in the vitamin D pathway in a cohort of SARS-CoV-2-positive patients from the
UAE population to investigate the possible association with COVID-19 disease severity.
The data presented here indicated a significant correlation between specific variants of the
GC, VDR, and DHCR7/NADSYN1 genes and susceptibility to severe COVID-19 infection.
The results showed that being older, having higher BMI, and the presence of one
or more comorbidities were important risk factors for developing a critical COVID-19
condition among SARS-CoV-2-positive patients. These findings are consistent with previously reported data regarding COVID-19 susceptibility and risk factors from several
populations [12,13]. Moreover, severe vitamin D deficiency was an independent risk factor
for the critical condition, in accordance with previous reports [14–16].
Genotype data were analyzed in relation to patients’ vitamin D levels, revealing
the involvement of vitamin D homeostasis and its metabolic pathway in influencing
susceptibility to severe COVID-19 disease. These genotypic differences in COVID-19
disease outcome could be attributed to vitamin D’s role in host immunity against SARSCoV-2 or other viral infections [17,18].
The results here also highlighted the genetic contribution of specific haplotypes for
VDR, DHCR7/NADSYN1, and GC genes to COVID-19 critical condition, emphasizing
the importance of genotypic variations in determining disease severity in populations.
For example, the AA genotype in SNP rs59241277, CC genotype in SNP rs113574864, GG
genotype in SNP rs182901986, TT genotype in SNP rs60349934, and GG genotype in SNP
rs113876500 in gene GC were associated with critical COVID-19 condition. The AA genotype in SNP rs4944076, GG genotype in SNP rs4944997, GG genotype in SNP rs4944998, GG
genotype in SNP rs4944979, and AA genotype in SNP rs10898210 in DHCR7/NADSYN1
gene were similarly associated with severity, whereas for gene VDR, the TT genotype in
SNP rs11574018 and GG genotype in SNP rs11574024 were significant.
A recent study by Kotur and colleagues (2021) reported a significant association
between specific genetic variants of DHCR7/NADSYN1 rs12785878, GC rs2282679, CYP2R1
rs10741657, and VDR rs2228570 and severe clinical outcomes among Serbian adults but
not among pediatric patients [8]. The findings in this study are consistent with results of
their study, though in this study no significant correlation was evident between COVID-19
clinical conditions and CYP2R1 genetic variants.
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AlSafar and colleagues (2021) recently reported that severe vitamin D deficiency
strongly correlated with COVID-19 severity and death among the UAE population [9].
Furthermore, several studies have shown that genetic polymorphisms in the VDR gene
affect susceptibility to certain chronic diseases, such as diabetes and obesity [10]. Our group
investigated the association of genetic variants within VDR and other genes important in
vitamin D metabolism with type 2 diabetes among Emiratis and concluded that a strong
association existed with risk of disease for specific variants [19,20]. In a similar context,
we showed the implications of such genetic variants in susceptibility to obesity among
young Arabs in the UAE [21]. Thus, exploring the relation of genetic variants involved
in vitamin D metabolism and COVID-19 severity is worth considering and might offer
population-based tools to identify individuals at greater risk of developing severe disease
outcomes. Such strategies, which depend on functional polymorphism, could lead to
implementing future protective measures in conjunction with vaccination [4,5,8].
A study that examined the effect of GC genetic variability in 913 infants on 25(OH)D
concentrations and the response to supplementation demonstrated that vitamin-D-binding
protein (DBP) polymorphisms affected the efficacy of vitamin D supplementation and
vitamin D status [22]. In addition, similar studies highlighted the role of GC genotypic
variation in determining the efficacy of vitamin D supplementation in pregnant women [23].
Physiologically, DBP can play an important role in determining vitamin D status by
controlling levels of both total and free vitamin D metabolites. DBP is extremely polymorphic, with variants exhibiting differences in biological function and being associated with
several pathophysiological conditions, including susceptibility to viral infections such as
hepatitis C [24–26]. A study by Batur and Hekim (2019) evaluated the link between polymorphisms of the DBP-encoding gene GC at specific loci and COVID-19 positivity/death
among several populations across 10 countries. The findings revealed a protective effect
for the TT genotype at the rs7041 locus and a susceptibility risk effect for the GT genotype
(p < 0.05) at the same locus among all populations. The results suggested an important
role for the genetic variants of GC in explaining disparities in the prevalence of COVID-19
infection and its mortality rates in the context of vitamin D metabolism [27].
Several cytochrome P450 enzymes are involved in vitamin D metabolism. CYP2R1
is one of those enzymes that play a key role in vitamin D hydroxylation [28]. Several
researchers have evaluated the relation between genetic variants of CYP2R1 and vitamin D
status among populations and have concluded that a robust correlation existed between
specific polymorphisms on SNPs (rs10766197 and rs10741657) and risk of vitamin D
deficiency [29,30]. Interestingly, knockout experiments in mice showed that CYP2R1
activity on vitamin D hydroxylation could be compensated for by another unidentified
enzyme [31].
One study of the Arabian and South Asian populations in Kuwait showed that CYP2R1
SNPs (rs10500804 and rs12794714) were significantly correlated with serum 25(OH)D
levels among the Arabian group but not among the South Asians [32]. That finding is
in agreement with findings from this study because the population in our investigation
consisted predominantly of South Asians, not Arabs (290 individuals from South Asia,
40 Arabs, and 23 from other ethnicities). Further research on the ethnicities of the UAE
population with a good sample size is thus needed to yield a broad picture about the
implications of genetic determinants of CYP2R1 on vitamin D status and before generalizing
findings to all races and ethnicities in the UAE population.
To the best of our knowledge, this study is the first to evaluate the contribution of
genetic variants of vitamin D metabolism to COVID-19 disease severity in the context
of 25(OH)D levels among a cohort of patients who tested positive for SARS-CoV-2 in
the UAE. Our findings could pave the way for future investigations aiming to examine
the potential role of variants of vitamin-D-related genes in altering not only COVID-19
disease outcome and transmission in this population but also response to vaccination
on the basis of vitamin D status and immune responses. Results could be projected to
guide future innovative and unique modeling with other viral respiratory diseases by
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using a personalized genotype-based approach that could be particularly valuable for
multiethnic populations.
Despite the strengths of our study, some limitations should be acknowledged. The
association between the genetic polymorphism of the genes studied and mortality was
not investigated because of the few deaths in the study. A larger sample size, which
affords the opportunity to examine death as an endpoint, could offer more insights into
the relation between the genetic determinants of vitamin D status and the death arising
from SARS-CoV-2 infection. Moreover, some socioeconomic data were not available to
explore the effect of UVB exposure, clothing habits, and dietary vitamin D intake on the
contribution of polymorphisms to 25(OH)D concentrations and course of COVID-19. The
vitamin D status of participants could have been affected by the use of supplements, but
that information was not recorded. In addition, the analytical methods for measuring
vitamin D in this study could affect the reading, and therefore, it is suggested that they
should be evaluated using LC-MS/MS [33].
5. Conclusions
The findings described here showed that variability in the genetic determinants of
vitamin D bioavailability and metabolism could play a role in modulating COVID-19
outcome among affected people in the UAE. These preliminary results could pave the
way for future investigations about the role of vitamin D status and supplementation
in conjunction with genotypic profile in reducing the severity of COVID-19 and risk
of infection. The implications of our research could also be informative for improving
treatment options by identifying individuals at risk of developing more severe outcomes
after infection on the basis of a personalized genetic profile, which could complement
the vaccination and vitamin D supplementation approach for improving assessment of
treatment. Larger studies and randomized clinical trials are warranted to fully decipher
the link between vitamin D homeostasis and genetic determinants and COVID-19 severity
among the multiethnic UAE population.
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230 SNPs), VDR (Chr. 12: 48235320-48298777; 154 SNPs) and CYP2R1 (Chr. 11: 14898986-14913777;
9 SNPs).
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